CERUS CORP

Listed Company

CERSCIK 0001020214NasdaqAcceleratedSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

$233.80M

Net Income

$-15.63M

Total Assets

$221.86M

Equity

$64.22M

Shares Out

200.37M

Op. Cash Flow

$4.84M

Business

CERUS CORP develops and commercializes the INTERCEPT Blood System to enhance blood safety by inactivating blood‑borne pathogens in donated blood components. Its main products and product candidates include pathogen‑reduction systems and disposable kits for platelets, plasma, cryoprecipitation (IFC) and a red blood cell system in development, plus related illuminators and inactivation compounds. The company operates commercial, clinical development and manufacturing/supply activities, sells IFC and kits, and engages in government contracts and joint venture arrangements. It distributes products directly to blood centers and hospitals and through regional distributors across the U.S., Europe, CIS, Middle East, Latin America, Asia‑Pacific and selected other markets.

Summary from filing dated 2025-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	234	201	187	188	160
Research and development	68	59	68	64	64
Selling, general and administrative	81	76	76	83	81
Restructuring	—	0	4	—	—
Total operating expenses	149	135	147	147	145
Loss from operations	−9	−14	−30	−34	−49
Foreign exchange (loss) gain	−1	370,000	−648,000	−690,000	−572,000
Interest expense	−8	−9	−8	−6	—
Other income, net	3	2	2	−2	374,000
Total non-operating expense, net	−7	−7	−7	−8	−5
Loss before income taxes	−15	−21	−37	−42	−54
Provision for income taxes	354,000	205,000	325,000	488,000	319,000
Net loss	−16	−21	−38	−43	−54
Net loss attributable to noncontrolling interest	−10,000	−43,000	−158,000	−46,000	−2,000
Net loss attributable to Cerus Corporation	−16	−21	−37	−43	−54
Basic (per share)	−0.08	−0.11	−0.21	−0.24	−0.32
Diluted (per share)	−0.08	−0.11	−0.21	−0.24	−0.32
Basic (shares)	191	185	180	177	171
Diluted (shares)	191	185	180	177	171

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	20	20	12	36	49
Short-term investments	63	60	54	67	81
Accounts receivable, net	30	30	36	34	25
Current inventories	56	38	40	29	27
Prepaid and other current assets	5	4	3	5	6
Total current assets	174	152	144	170	187
Property and equipment, net	9	7	9	11	12
Operating lease right-of-use assets	10	8	11	13	13
Goodwill	1	1	1	1	1
Restricted cash	639,000	1	2	2	2
Non-current inventories	15	14	20	15	—
Other assets	11	17	11	6	22
Total assets	222	201	198	218	237
Accounts payable	28	22	24	33	36
Accrued liabilities	25	19	19	25	26
Debt current	43	19	20	56	15
Operating lease liabilities current	3	2	2	2	2
Deferred revenue	1	1	2	589,000	673,000
Total current liabilities	101	64	68	117	79
Debt non-current	41	65	60	14	55
Operating lease liabilities non-current	10	12	14	15	16
Other non-current liabilities	5	4	3	3	2
Total liabilities	157	144	144	150	152
Commitments and contingencies (Note 10)	—	—	—	—	—
Preferred stock, $0.001 par value; 5,000 shares authorized, issuable in series; zero shares issued and outstanding at December 31, 2025 and 2024, respectively	—	—	—	—	—
Common stock, $0.001 par value; 400,000 and 400,000 shares authorized; 192,142 and 185,766 shares issued and outstanding at December 31, 2025 and 2024, respectively	192,000	186,000	181,000	177,000	174,000
Additional paid-in capital	1,145	1,122	1,098	1,077	1,049
Accumulated other comprehensive loss	−156,000	−400,000	−1	−3	−149,000
Accumulated deficit	−1,081	−1,066	−1,045	−1,007	−964
Total Cerus Corporation stockholders' equity	64	56	53	68	85
Noncontrolling interest	741,000	751,000	794,000	952,000	998,000
Total liabilities and stockholders' equity	222	201	198	218	237

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	1	2	3	3	3
Stock-based compensation	23	23	20	24	24
Non-cash operating lease cost	3	2	2	2	1
Net (gain) loss on sale of available-for-sale securities	−6,000	7,000	54,000	108,000	−21,000
Unrealized gain on investments	−204,000	−135,000	−170,000	−564,000	−267,000
Loss on disposal of fixed assets	—	3,000	65,000	—	—
Impairment charges for facilities consolidation	0	0	2	0	—
Non-cash interest expense	398,000	398,000	374,000	609,000	591,000
Foreign currency remeasurement loss (gain)	290,000	−388,000	−685,000	2	511,000
Accounts receivable	−396,000	6	−1	−9	−4
Inventories	−15	7	−15	−2	−20
Prepaid and other assets	−2	−3	−994,000	1	3
Accounts payable	6	−1	−7	−5	12
Accrued liabilities and other non-current liabilities	4	−2	−9	−1	47,000
Deferred revenue	−124,000	−603,000	1	−84,000	96,000
Net cash provided by (used in) operating activities	5	11	−43	−26	−34
Capital expenditures	−4	−3	−5	−2	−910,000
Purchases of investments	−43	−43	−2	−30	−52
Proceeds from maturities and sale of investments	40	38	16	40	66
Net cash (used in) provided by investing activities	−6	−8	9	8	13
Net proceeds from equity incentives	595,000	804,000	925,000	4	9
Net costs from public offerings	−35,000	−137,000	−175,000	−104,000	3
Net (payments on) proceeds from revolving line of credit	−329,000	−703,000	5	212,000	—
Proceeds from loans, net of issuance costs	—	5	5	—	15
Net cash provided by financing activities	231,000	5	11	4	34
Effect of exchange rates on cash, cash equivalents, and restricted cash	336,000	−191,000	−128,000	−727,000	−919,000
Net (decrease) increase in cash, cash equivalents, and restricted cash	−761,000	8	−24	−14	12
Cash paid for interest	9	9	9	5	4
Cash paid for income taxes	301,000	356,000	322,000	270,000	278,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro